Hüseyin DUMANLI, Serdar OGUZ, Emre Sinan GÜNGÖR, Leyla MOLLAMAHMUTOĞLU, İlker GÜNYELİ

Distribution of mammographic densities ın 5052 women at the perımenopausal and postmenopausal stage

Mamografide saptanan kitlelerin, meme dansitesinin ve benign özellikteki kalsifikasyonların yaşlara göre dağılımını ve sıklıklarını saptamak ve HRT’nin meme dansitesi üzerindeki etkisini değerlendirmek. Metod: Ocak 2001 ve Ocak 2004 tarihleri arasında Dr. Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi menapoz polikliniğine başvuran 5052 hastanın mamografileri değerlendirildi. Her meme dansitesi BIRADS sistemine göre dört gruptan birinde olacak şekilde değerlendirildi. Hastalarda saptanan mamografik kitleleler ve benign özellikteki kalsifikasyonlar not edildi. Hastaların HRT kullanma durumları değerlendirildi. İstatistiksel incelemeler için ki-kare ve Spearman korelasyon testleri kullanıldı ve p

Perimenopozal ve postmenopozal dönemindeki 5052 hastanın mamografik dansitelerinin dağılımı

To establish the frequency and age distribution of breast tissue density, mammographic masses and benign calcifications and to study the effect of hormone replacement therapy (HRT), which has been suggested to affect parenchymal density on mammograms. Methods: The mammograms of all patients attending the Zekai Tahir Burak Women Health Education and Research Hospital menopause clinic between January 2001 and January 2004 were evaluated. We reviewed 5052 women. The density for each breast was classified into one of four groups as defined by the BI-RADS system. For each patient, benign or probably benign calcifications were also recorded. The use of HRT was recorded systematically for every patient. Chi-square and Spearman correlation tests were performed. The statistical significance of observed differences was set at p

PDF

___

1- Kerlikowske K, Grady D, Susan M. Efficacy of screening mammography. A meta analysis. JAMA; 1995; 273: 2.
2- Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res. 2006; 66: 1866-72.
3- Tabar L, Fagerberg G, Duffy S, Day N, Gas A, Grontoft O. Update of the Swedish two county program of mammographic screening trial. Radiol Clin North Am.1992; 30: 187-210.
4- Andersson I, Aspegren K, Janzon L et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ. 1988; 297: 943-948.
5- Roberts MM, Alexander FE, Anderson TJ et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet. 1990; 335: 241-246.
6- Frisll J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening:preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat. 1991; 18: 49-56.
7- Shapiro S. Periodic screening for breast cancer: The Health Insurance Plan Project and Its Sequelae, 1963-1986. Baltimore, Md: Johns Hopkins University Press; 1988.
8- Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study, 1: breast cancer detection death rates among women aged 40 to 49 years. Can Med Assoc J. 1992; 147: 1459-1476.
9- Warner E, Lockwood G, Tritchel D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a metaanalysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992; 16: 67-72.
10- Kato I, Beinart C, Bleich A, Su S, Kim M. A nested case control study of mammographic patterns, breast volume and breast cancer. Cancer Causes Control 1995; 6: 431-8.
11- Salminen T, Saarenmaa I, Heikkila M, Hakama M. Risk of breast cancer and changes in mammographic parenchymal patterns over time. Acta Oncol 1998; 37: 547-51.
12- Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Do age, breast density, and family history affect the sensitivity of first screening mammography? JAMA 1996; 276: 33-38.
13- Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995; 196: 433-7.
14- McNicholas MMJ, Heneghan JP, Milner MH, Tunney T. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. Am J Roentgenol 1994; 163: 311-5.
15- Liberman L, Menell J. Breast imaging reporting and data system (BIRADS). Radiol Clin N Am 2002; 40: 409-430.
16- Flobbe K, Nelemans PJ, Kessels AGH, Beets GL, Von Meyenfeldt MF. The role of ultrasonography as an adjunct to mammography in the detection of breast cancer: a systematic review. Eur J Can 2002; 38: 1044-1050.
17- Powell RW, McSweeney MB, Wilson CE. X-ray calcifications as the only basis for breast biopsy. Ann Surg 1983; 197: 555-559.
18- Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y,Shimizu H. Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer. 2005; 92: 2102-6.
19- Maskarinec G, Pagano I, Lurie G, Wilkens LR, Kolonel LN. Mammographic density and breast cancer risk: the multiethnic cohort study. Am J Epidemiol. 2005; 162: 743-52.
20- Mandelson MT, Oestreicher N, Porter P, White D, Finder C, Taplin S, et al. Breast density as a predictor of mammographic detection: Comparison of ınterval- and screen-detected cancers. J Nat Can Ins 2000; 92: 1081-1087.
21- Salminen T, Saarenmaa I, Heikkila M, Hakama M. Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy? Acta Oncologica 2000; 39: 969-72.
22- Patella A, Marziani R, Schippa A, Benedetti S, Mossa S, Mossa B. Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specificity and sensitivity of mammographic screening. Eur J Gynaecol Oncol. 2005; 26: 485-90.